



BIODIEM LTD  
ABN 20 096 845 993  
Level 4,  
100 Albert Road,  
South Melbourne, Victoria, 3205  
Australia  
Phone: +613 9692 7240  
Web: [www.biodiem.com](http://www.biodiem.com)

## Announcement

### Company Update and EOFY 2024 Information

**Melbourne, 4 July 2024:** Australian vaccine development company BioDiem Ltd today and its subsidiary company Opal Biosciences Ltd (“Opal”) are pleased to provide the following update.

#### **BioDiem Ltd (“BioDiem”)**

China-based Changchun BCHT Biotechnology Co (BCHT) holds an exclusive licence from BioDiem for the vaccine technology based on the live attenuated influenza virus (LAIV). BCHT’s licence covers the private sector market in China for pandemic and seasonal influenza vaccines made using an egg-based production method. BCHT holds a complementary licence to the LAIV for the public market in China via a sublicense from the World Health Organisation. BioDiem received a payment from BCHT of US\$249,960 in March 2024.

At a General Meeting held on 19 April 2024 BioDiem shareholders passed the advisory resolution: “That it is in the best interests of and to the further commercial benefit of the Company to and that the Company enter into a transaction (or a series of transactions) pursuant to which the Company’s major asset, being the licence rights to the influenza vaccine (LAIV) technology, is sold to such third parties, and on such terms and conditions, as the Board determines in its sole discretion.” BioDiem has commenced discussions with interested parties.

#### **Opal Biosciences Ltd (“Opal”)**

On 27 May 2024 Opal announced that its Information Memorandum dated 1 September 2023, which sought to raise up to \$2.5million (Capital Raising), closed on Friday 24 May 2024. The Capital Raising required a minimum subscription amount of \$2million. This target was not reached by the closing date. All application monies received have been returned in full (without interest) to applicants.

On 6 June 2024 Opal issued a Notice of General Meeting of Shareholders for a meeting to be held on 28 June 2024. On 27 June Opal announced that the meeting was postponed until a date and time to be notified in due course.

Opal is currently exploring and progressing discussions with strategic third parties to see if Opal could enter into a potential transaction.

#### **EOFY Share Price information\***

The EOFY 2024 share price information is as follows being the pricing of the last capital raise:

- BioDiem ordinary shares = \$0.08 (8 cents)
- BioDiem preference shares = \$0.08 (8 cents)

For those BioDiem shareholders who also separately hold shares in Opal, the EOFY 2024 share price of Opal Biosciences ordinary shares is \$0.075 (7.5 cents) being the pricing of the last capital raise.

\*The Company does not provide any advice regarding valuation, and shareholders are encouraged to seek their own professional advice in relation to valuation of their shares.

#### **Shareholder Information at Share Registry, Computershare.**

Shareholders are asked to ensure their contact details/email addresses are up-to-date at Computershare. This can be done online via the Computershare Investor Centre ([www.computershare.com.au](http://www.computershare.com.au)).

- ENDS -

**Further information**

Julie Phillips, Chief Executive Officer  
BioDiem Ltd  
Phone +61 3 9692 7240  
Email [jphillips@biodiem.com](mailto:jphillips@biodiem.com)